José Eduardo Vidal

Chief Executive Officer at Cytoimmune Therapeutics, Inc.

Health Technology

Consumer Services

Profile

José Eduardo Vidal is currently the Chief Executive Officer & Director at Cytoimmune Therapeutics, Inc. He previously worked as the Senior Vice President-Quality & Process Sciences at Atara Biotherapeutics, Inc. Dr. Eduardo Vidal completed his undergraduate degree at the University of Puerto Rico.

José Eduardo Vidal active positions

Companies	Position	Start
Cytoimmune Therapeutics, Inc. Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.	Chief Executive Officer	17/07/2023

All active positions of José Eduardo Vidal

Former positions of José Eduardo Vidal

Companies	Position	End
ATARA BIOTHERAPEUTICS, INC.	Corporate Officer/Principal	-

See the detail of José Eduardo Vidal's experience

Training of José Eduardo Vidal

University of Puerto Rico

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of José Eduardo Vidal's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ATARA BIOTHERAPEUTICS, INC.	Health Technology

Private companies	1
Cytoimmune Therapeutics, Inc. Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.	Health Technology